Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison
ConclusionsThis indirect treatment comparison indicates a statistically significant and clinically relevant difference in ABR favouring individualised prophylaxis with rFVIIIFc versus BAY 94-9027 prophylaxis. The proportion of patients with zero bleeds was numerically greater with rFVIIIFc treatment but did not achieve statistical significance.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Bleeding | Clinical Trials | Drugs & Pharmacology | Haemophilia | Hemophilia | Statistics | Study